CRISM Therapeutics (CRTX) Share Price, News & Analysis

Company Overview

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed® in high-grade glioma. Based on preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform clinical trial which is an efficient and cost-effective clinical development opportunity. For more information please visit: https://www.crismtherapeutics.com

Key Stats

• Today's Range: 15.16 to 29.40
• 50-Day Range: 6 to 21.76
• 52-Week Range: 5 to 30.90
• Volume: 887,944 shs
• Average Volume: 40,562 shs
• Market Capitalization: £2.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRTX Stock Analysis - Frequently Asked Questions

How have CRTX shares performed this year?

CRISM Therapeutics' stock was trading at GBX 10 at the start of the year. Since then, CRTX shares have increased by 117.6% and is now trading at GBX 21.76.
View the best growth stocks for 2025 here.

How do I buy shares of CRISM Therapeutics?

Shares of CRTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Basic Materials
• Industry: Other Industrial Metals & Mining
• Sub-Industry: N/A
• Current Symbol: LON:CRTX
• CIK: N/A
• Web: www.crismtherapeutics.com
• Phone: N/A
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (5.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-792,204.93
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -13.12%
• Return on Assets: -26.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.56
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 43.03 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 10,894,261
• Free Float: N/A
• Market Cap: £2.37 million
• Optionable: N/A
• Beta: 0.81